BARDA awarded SCYNEXIS (NASDAQ:SCYX) a contract worth up to approximately $214 million in potential funding puts SCY-247 at the center of a much bigger public-health and biotech narrative: the race to develop new weapons against increasingly drug-resistant fungal infections.
BARDA awarded SCYNEXIS (NASDAQ:SCYX) a contract worth up to approximately $214 million in potential funding puts SCY-247 at the center of a much bigger public-health and biotech narrative: the race to develop new weapons against increasingly drug-resistant fungal infections.
Gainers
Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion.
SCYNEXIS (NASDAQ:SCYX) stock increased by 15.7%read more...
Gainers
Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session.
SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding shares is atread more...
U.S. stock futures are up, with investor focus on quarterly earnings from AutoZone, Elbit Systems, SCYNEXIS, Box, and Zscaler after the closing bell.read more...
(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million...